Mechanism of Action

Asthma: From Medieval Pregnant Cows to Albuterol - The Discovery of Beta Agonists

17 min · I går
episode Asthma: From Medieval Pregnant Cows to Albuterol - The Discovery of Beta Agonists cover

Beskrivelse

Medieval peasants, poisonous rye fungus, racing hearts, and one of the most important inhalers ever invented. In this episode, Dr. Adam J. Brown continues the asthma series with the strange history of beta-2 agonists and albuterol. We begin with ephedra, ephedrine, and early plant-based asthma treatments, then follow the trail through ergot-contaminated rye, Henry Dale’s experiments with ergotamine and adrenaline, and the discovery that the sympathetic nervous system was working through more than one receptor. From there, we trace Raymond Ahlquist’s alpha/beta receptor breakthrough, the rise of epinephrine and isoproterenol as asthma therapies, the asthma death epidemic of the 1960s, and the leap that separated beta-1 from beta-2 receptors. That discovery opened the door to albuterol—an inhaler designed to target the lungs more than the heart, and still one of the most important rescue treatments in asthma.

Kommentarer

0

Vær den første til å kommentere

Registrer deg nå og bli medlem av Mechanism of Action sitt community!

Prøv gratis

Prøv gratis i 14 dager

99 kr / Måned etter prøveperioden. · Avslutt når som helst.

  • Eksklusive podkaster
  • 20 timer lydbøker i måneden
  • Gratis podkaster

Alle episoder

10 Episoder

episode Asthma: From Medieval Pregnant Cows to Albuterol - The Discovery of Beta Agonists cover

Asthma: From Medieval Pregnant Cows to Albuterol - The Discovery of Beta Agonists

Medieval peasants, poisonous rye fungus, racing hearts, and one of the most important inhalers ever invented. In this episode, Dr. Adam J. Brown continues the asthma series with the strange history of beta-2 agonists and albuterol. We begin with ephedra, ephedrine, and early plant-based asthma treatments, then follow the trail through ergot-contaminated rye, Henry Dale’s experiments with ergotamine and adrenaline, and the discovery that the sympathetic nervous system was working through more than one receptor. From there, we trace Raymond Ahlquist’s alpha/beta receptor breakthrough, the rise of epinephrine and isoproterenol as asthma therapies, the asthma death epidemic of the 1960s, and the leap that separated beta-1 from beta-2 receptors. That discovery opened the door to albuterol—an inhaler designed to target the lungs more than the heart, and still one of the most important rescue treatments in asthma.

I går17 min
episode Asthma: Dreams of Anticholinergics cover

Asthma: Dreams of Anticholinergics

Asthma treatment wasn’t always built around inhalers. It once came from poisonous plants, smoke, and a mysterious dream. In this episode, we explore the strange history of anticholinergics, tracing the path from Jimsonweed and belladonna to atropine, acetylcholine, and Otto Loewi’s discovery of “Vagusstoff.” We follow how Loewi’s frog-heart experiment helped prove that nerves communicate through chemical messengers, and how Henry Dale’s work connected those discoveries to the vagus nerve and airway constriction. We examine why early plant-based asthma remedies could open the airways while also causing dangerous side effects, and how that understanding eventually led to modern anticholinergic therapy. This episode reveals how a dream, a frog heart, and a toxic smoke helped shape the pharmacology of asthma.

16. mai 202624 min
episode Breaking the RAAS Cycle: ACE Inhibition in Heart and Kidney Disease cover

Breaking the RAAS Cycle: ACE Inhibition in Heart and Kidney Disease

From the discovery of a mysterious blood-pressure–lowering effect in the venom of a Brazilian pit viper to the development of the first ACE inhibitor, we trace how scientists transformed a deadly toxin into lifesaving medicine. We follow the work that identified bradykinin-potentiating peptides in snake venom and revealed that angiotensin-converting enzyme could be blocked—leading to the creation of captopril and later drugs such as enalapril and lisinopril. Along the way, landmark experiments and clinical trials showed that ACE inhibitors do far more than lower blood pressure, reshaping the treatment of heart failure and chronic kidney disease by targeting maladaptive activation of the renin–angiotensin–aldosterone system.

12. mars 202626 min